

Special Issue

Novel Adjuvants and Delivery Technologies for Vaccine Development

Message from the Guest Editors

The development of effective vaccines is crucial in combating infectious and non-infectious diseases and enhancing public health. Novel adjuvants and delivery technologies are essential for optimizing vaccine efficacy, as they can significantly improve immune responses and broaden the protective effects of vaccines.

We welcome submissions that encompass a range of topics, including but not limited to the following:

- Innovative Adjuvant Development: Exploration of new adjuvants that enhance immune responses.
- Targeted Delivery Systems: Research on systems that improve the specificity of antigen delivery.
- Nanotechnology in Vaccines: Studies on the application of nanomaterials for vaccine formulation.
- Clinical Efficacy Studies: Reports on clinical trials evaluating novel adjuvants and delivery methods.
- Mechanisms of Action: Investigations into how adjuvants and delivery technologies influence immune pathways.
- Combination Vaccines: Research on using adjuvants and delivery systems in multi-antigen formulations.

We look forward to receiving your contributions.

Guest Editors

Dr. Mohammad N. Uddin

College of Pharmacy, Mercer University, Atlanta, GA 30341, USA

Dr. Bernadette D'Souza

Department of Pharmaceutical, Social and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL 35229, USA

Deadline for manuscript submissions

31 March 2027



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/240992

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).